UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Jun

    27

    Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis

    Read More

    Jun

    27

    UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

    Read More

    Jun

    14

    How UCB Is Supporting the Mental Health of Patients and Caregivers

    Read More

    Jun

    14

    Recognizing Ethical Leadership at UCB

    Read More

    Jun

    02

    Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome

    Read More

    Jun

    01

    Myasthenia Gravis Awareness Month is the Time to Understand More About the Lived Experiences of the Community

    Read More

    © 2009 - 2026 UCB, Inc. Atlanta. All rights reserved. 
    Last updated: March 2026